FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
Teva, Mylan, and Sandoz announced the US launches of their generic equivalents to Novartis’s Exforge.
Medtronic’s CoreValve System is now approved for first-of-its-kind “valve-in-valve” replacement.
A veritable alphabet soup of hypertension guidelines have been released over the past year. Here is what you need to know.
Veterans with post-traumatic stress disorder face greater odds of developing heart failure.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$